EASD 2025: Orforglipron in Focus, the Case for Cardiovascular Benefits, More
While Eli Lilly’s orforglipron is top of mind heading into the European Association for the Study of Diabetes meeting this week, experts told BioSpace the conference will also provide important insights into the therapeutic benefits of incretin therapies beyond weight loss.
EASD 2025: Orforglipron in Focus, the Case for Cardiovascular Benefits, More Read More »
